What were the key takeaways from Insmed’s earnings call?

What is Insmed's latest dividend and current dividend yield?

What does Insmed do and what are its main business segments?

What guidance did Insmed's management provide for the next earnings period?

What were the key takeaways from Insmed's earnings call?

What is Insmed's gross profit margin?

What factors drove the changes in Insmed's revenue and profit?

What is the revenue and EPS growth rate for Insmed year over year?

**【Key Takeaways】**
- **BRINSUPRI Milestone**: 2026 revenue guidance of $1+ billion, with >$5 billion peak potential. 
- **Market Expansion**: 32 million COPD/asthma patients could be eligible if diagnosed with bronchiectasis. 
- **Financial Strength**: $1.4 billion cash; no capital needed for 2026 cash flow positivity. 
- **Pipeline Momentum**: TPIP Phase III for PAH, ENCORE trial to expand ARIKAYCE label. 
- **Execution Confidence**: BRINSUPRI Q4 2025 revenue exceeded expectations, GTN stable at mid-20s%. 


**【CEO Summary Section】**
- BRINSUPRI revenue guidance for 2026: At least $1 billion, driven by U.S. launch and potential expansion into COPD/asthma patients. 
- BRINSUPRI Q4 2025 net revenue: $144.6 million, exceeding pre-launch expectations. 
- Peak sales estimate for BRINSUPRI: >$5 billion (250,000 diagnosed patients with ≥2 exacerbations), with upside from 32 million COPD/asthma patients. 
- ARIKAYCE 2025 growth: 40% in Japan, Europe growth acceleration; ENCORE trial expected to expand NTM addressable market to >200,000 patients. 
- TPIP orphan drug designation for PAH; Phase III trial (PALM-PAH) to begin H1 2026. 
- Cash flow positivity achievable in 2026 without additional capital, but open to BD for pipeline expansion. 

**【CFO Financial Commentary】**
- Q4 2025 cash position: $1.4 billion (excluding one-time items). 
- BRINSUPRI gross-to-net (GTN) guidance 2026: Mid-20s to low-30s%, stable vs. 2025. 
- ARIKAYCE GTN 2026: Low to mid-20s%, slight increase due to IRA provisions. 
- R&D and SG&A expenses increasing to support BRINSUPRI launch and pipeline. 
- Path to cash flow positivity: Driven by BRINSUPRI and ARIKAYCE revenue growth. 

**【Q&A Highlights】**
- BRINSUPRI persistence: Refill rates strong, 6-month data positive; 1-year mark key for long-term adherence. 
- Market access: >90% of targeted lives have favorable reimbursement (attestation or doc-based). 
- COPD/asthma strategy: Educating pulmonologists to identify bronchiectasis via CT scans. 
- Business development: Open to Phase II+ assets with first/best-in-class potential. 
- ENCORE trial: Expected H2 2026 readout; culture conversion primary endpoint for Japan, PRO secondary for U.S. 


Insmed Incorporated (INSM) Q4 2025 Earnings Call Transcript

- **BRINSUPRI Launch Momentum**: $28M in 6 weeks, 2,550 patients, and broad prescriber adoption, despite early-stage uncertainty.
- **Pipeline Progress**: EU brensocatib approval expected in 2025, BiRCh and CEDAR trials on track, and TPIP Phase III启动.
- **Financial Strength**: $1.7B cash, ARIKAYCE guidance raised to $420-430M, and robust pipeline funding.
- **Clinical Catalysts**: ENCORE readout in 2026, BiRCh results in early 2026, and multiple Phase III starts in 2026.


**【CEO Summary Section】**
- Launched BRINSUPRI in the U.S., achieving $28M in net sales in the first 6 weeks, with 2,550 patients and 1,700 prescribers. Emphasized cautious optimism due to early data complexity.
- Highlighted pipeline progress: EU CHMP positive opinion for brensocatib, Phase II BiRCh study in CRS without nasal polyps nearing completion, and CEDAR trial in hidradenitis suppurativa fully enrolled.
- ARIKAYCE revenue up 22% YoY, driven by U.S. and international growth, with potential for expansion into Japan and Europe.

**【CFO Financial Commentary】**
- Raised 2025 ARIKAYCE net revenue guidance to $420-430M (prev. $405-425M), reflecting strong commercial execution.
- Cash position of $1.7B supports BRINSUPRI launch and pipeline investments.
- Q3 2025 R&D and SG&A expenses increased due to BRINSUPRI launch and pipeline expansion.

**【Q&A Highlights】**
- **BRINSUPRI Market Access**: Early ease of access, with focus on 2+ exacerbations criteria; 40% of Q3 sales attributed to channel stocking.
- **BiRCh Study**: 80% powered to detect 0.97 placebo-adjusted treatment effect; data lock expected by early 2026.
- **TPIP Development**: Single Phase III trial for PAH aligned with FDA; Phase III starts in PPF and IPF planned for 2026.
- **HS Pipeline**: CEDAR trial fully enrolled, targeting 20% AN count reduction; 95% powered for 40% reduction.
- **Gene Therapies**: DMD and ALS programs advancing in Phase I, with promising safety profiles.


Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript

- **Bronchiectasis launch confidence**: 90% of physicians intend to prescribe brensocatib; team built 10 months pre-approval with patient support infrastructure. 
- **ARIKAYCE growth**: Q2 revenue $112.3M (+15% YoY); on track for $405-425M 2025 guidance. 
- **TPIP breakthrough**: Phase II PAH data shows 35% PVR reduction; Phase III for PH-ILD and PAH expected 2025-2026. 
- **Financial fortress**: $1.9B cash post-equity raise; well-positioned for 2025-2026 catalysts. 
- **Pipeline expansion**: Next-gen DPP1 inhibitors targeting COPD, asthma, and IBD; first gene therapy trial dosed in DMD. 


**【CEO Summary Section】**
- **Late-stage portfolio success**: ARIKAYCE, brensocatib, and TPIP all show positive Phase II/III data, with brensocatib on track for U.S. launch in bronchiectasis. 
- **Commercial readiness**: Sales team built 10 months pre-launch; patient support program (Enlighten) operational; 90% of surveyed physicians intend to prescribe brensocatib. 
- **Pipeline expansion**: TPIP Phase III for PH-ILD and PAH expected in 2025-2026; next-gen DPP1 inhibitors targeting COPD, asthma, and IBD. 
- **Early-stage research**: 30+ preclinical programs; first gene therapy trial (DMD) dosed; INDs anticipated for ALS and Stargardt disease. 

**【CFO Financial Commentary】**
- **ARIKAYCE revenue growth**: Q2 2025 net revenue $112.3M (15% YoY), driven by U.S. ($45.5M, +28%), Japan (+45%), and Europe (+48%). Full-year guidance $405-425M. 
- **Financial strength**: $1.9B cash post-$823M equity raise; operating expenses up due to launch prep and pipeline investments. 
- **Cash position**: Well-capitalized for 2025-2026 catalysts, including brensocatib launch and TPIP trials. 

**【Q&A Highlights】**
- **Launch mechanics**: Proactive patient identification via CT scans; 2+ exacerbations criteria; no sampling, but co-pay support. 
- **Payer alignment**: Positive feedback on prior auth criteria (CT scan + 2+ exacerbations). 
- **TPIP potential**: Phase II data in PAH shows 35% PVR reduction; Phase III design discussions with FDA for 2026 start. 
- **HS futility analysis**: Focus on 100-patient interim for efficacy signal; no p-value required. 
- **Global expansion**: Europe and Japan launches for brensocatib in 2026; ARIKAYCE ENCORE study targeting 225K new MAC patients. 


Insmed (INSM)-7 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Growth**: ARIKAYCE delivers 14% US growth and 50% expansion in Japan/Europe, with 2025 guidance of $405M-$425M on track.
- **Brensocatib Regulatory Momentum**: FDA NDA review on track for August 12 PDUFA; international approvals targeted for 2026.
- **TPIP Trial Update**: Phase 2 readout expected June; 20% PVR reduction threshold for success, with 95% patient retention in open-label extension.
- **Financial Strength**: $1.2B cash balance supports pipeline; Q1 operating expenses down QoQ, with launch readiness investments offsetting.
- **Innovative Pipeline**: Next-gen DPP-1 inhibitors for COPD/Rheumatoid Arthritis expected in clinic by 2026; gene therapy programs advancing with intrathecal delivery approach.

**【CEO Summary Section】**
- **Q1 2025 Performance**: ARIKAYCE delivered double-digit year-over-year revenue growth, with Japan and Europe seeing 50% growth. The company is on track to meet 2025 ARIKAYCE net revenue guidance of $405M-$425M.
- **Brensocatib Regulatory Progress**: FDA review of the NDA for bronchiectasis is on track for the August 12 PDUFA date. International filings (Europe, UK, Japan) are progressing, targeting 2026 approvals.
- **Launch Readiness**: Over 1M unique visits to the disease awareness website, 53K patient actions, and 27K+ HCP engagements. Payer discussions are constructive, with focus on frictionless launch.
- **Pipeline Updates**: 
  - **BiRCh Trial (CRS w/o NP)**: Enrollment exceeded target (288/270), with blinded data trending positively; topline results expected by end-2025.
  - **TPIP (PAH)**: Phase 2 readout expected in June, with PVR reduction of 20% as success threshold. Open-label extension shows 95% patient retention at high doses.
  - **Next-gen DPP-1 Inhibitors**: First molecule expected in clinic by 2026, targeting COPD and rheumatoid arthritis.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: 
  - ARIKAYCE net revenue growth driven by strong volume trends (14% US, 50% Japan/Europe).
  - Cash balance of $1.2B supports upcoming clinical and commercial catalysts.
  - Operating expenses up YoY due to launch readiness and pipeline expansion, but down QoQ from Q4 2024.
- **Tariff Impact**: Estimated single-digit million annual impact, with US manufacturing expansion underway.
- **Convertible Debt Redemption**: $570M debt redemption expected June 6; conversion could add ~17.8M shares.

**【Q&A Key Highlights】**
- **Brensocatib Pricing Strategy**: Targeting upper half of $40K-$96K range, with gross-to-net ~25%-35% based on Medicare 60% patient mix and 20% catastrophic coverage.
- **TPIP Trial Design**: Phase 3 will use 6-minute walk distance as primary endpoint, with PVR reduction as key secondary metric. Dose titration up to 1,280mcg (double Phase 2 max) planned.
- **Gene Therapy Progress**: Intrathecal delivery approach for DMD aims to reduce immune reactions; first clinical candidates expected by mid-2025.
- **HS Trial Futility Analysis**: 100-patient interim evaluation will assess abscess/nodule count reduction; Phase 3 design will depend on signal strength.


Insmed (INSM)-8 May 25-2025 Q1 Earnings call transcript

- **Brensocatib Launch Momentum**: FDA priority review with August 2025 PDUFA date; U.S. launch targeting mid-August with pricing in upper $40K–$96K range. Market access strategy aims for 90%+ physician prescribing intent.
- **ARIKAYCE Growth**: 2024 revenue $363.7M (+19% YoY), 2025 guidance $405–$425M. ENCORE trial in Q1 2026 could expand label to all MAC lung disease patients.
- **Pipeline Expansion**: Phase 2 data for BiRCh (CRS without NP) and TPIP (PAH) expected mid-2025. Gene therapy programs (DMD, ALS, Stargardt) advancing to IND in 2025.

**【CEO Summary Section】**
- **Brensocatib Launch Update**: FDA accepted NDA for bronchiectasis under priority review with PDUFA date of August 12, 2025. Expected U.S. launch in mid-August with pricing in the upper half of $40,000–$96,000 range. Market access strategy focuses on frictionless prior authorization and reauthorization.
- **ARIKAYCE Performance**: 2024 net revenue $363.7M (+19% YoY), driven by U.S. ($254.8M, +14%), Japan ($87.7M, +33%), and Europe ($21.2M, +39%). 2025 guidance: $405–$425M, excluding brensocatib.
- **Pipeline Progress**: Phase 2 BiRCh trial for CRS without nasal polyps (expected 2025 data), Phase 2 TPIP in PAH (mid-2025 data), and Phase 3 ENCORE trial for ARIKAYCE in MAC lung disease (Q1 2026 readout).

**【CFO Financial Commentary】**
- **2024 Financials**: Full-year net revenue $363.7M, R&D/Sales & Admin expenses $599M/$462M. Cash balance $1.4B as of year-end, supporting 2025 launch preparations.
- **Gross to Net Expectations**: ARIKAYCE 2025 gross to nets ~17%–23% (IRRA impact). Brensocatib launch gross to nets ~25%–35%.
- **2025 Outlook**: ARIKAYCE revenue growth to $405–$425M, with brensocatib launch contributing from Q3 2025 onward.

**【Q&A Highlights】**
- **Market Access Strategy**: Brensocatib pricing and contracting to ensure 90%+ physician intent to prescribe. Minimal discounting for Medicare catastrophic coverage (20% by 2031 for ARIKAYCE).
- **Pipeline Catalysts**: BiRCh trial (CRS without NP) and TPIP Phase 2 PAH data expected mid-2025. Gene therapy programs (DMD, ALS, Stargardt) advancing to IND in 2025.
- **Bronchiectasis Addressable Market**: ~500K diagnosed patients, ~250K with ≥2 exacerbations. Patient engagement high (41K+ on disease awareness website).

Actual											-0.74	-0.64	-0.63	-1	-0.89	-1.07	-0.96	-0.95	-0.8	-0.8	-1.09	-1.21	-1.17	-1.78	-1.11	-1.28	-1.06	-1.94	-1.27	-1.32	-1.42	-1.7	-1.75	-1.54
Forecast											-0.7231	-0.62	-0.5929	-0.694	-0.9425	-0.8936	-0.8583	-0.8997	-0.882	-0.8871	-0.8786	-1.0465	-1.1277	-1.1338	-1.1411	-1.1531	-1.2377	-1.2444	-1.2021	-1.1708	-1.3373	-1.2993	-1.3286	-1.0714
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.34%	-3.23%	-6.26%	-44.09%	+5.57%	-19.74%	-11.85%	-5.59%	+9.30%	+9.82%	-24.06%	-15.62%	-3.75%	-56.99%	+2.73%	-11.01%	+14.36%	-55.90%	-5.65%	-12.74%	-6.18%	-30.84%	-31.72%	-43.74%

INSM

INSM fundamentals

INSM Q4 2025 Earnings

Earnings Call

You can ask Aime

INSM

INSM fundamentals

INSM Q4 2025 Earnings

Earnings Call

INSM Earnings Call Summary for Q4/20258:00 AM on Feb 19, 2026

INSM Earnings Call Summary for Q3/20258:00 AM on Oct 30, 2025

INSM Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

INSM Earnings Call Summary for Q1/20258:00 AM on May 8, 2025

INSM Earnings Call Summary for Q4/20248:00 AM on Feb 20, 2025

You can ask Aime